Stryker Co. (NYSE:SYK) Shares Purchased by Quest Investment Management LLC

Quest Investment Management LLC raised its holdings in Stryker Co. (NYSE:SYK) by 1.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,702 shares of the medical technology company’s stock after buying an additional 751 shares during the period. Stryker comprises about 1.8% of Quest Investment Management LLC’s holdings, making the stock its 20th largest position. Quest Investment Management LLC’s holdings in Stryker were worth $15,890,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of SYK. Precision Wealth Strategies LLC grew its position in shares of Stryker by 2.1% in the 4th quarter. Precision Wealth Strategies LLC now owns 3,114 shares of the medical technology company’s stock valued at $933,000 after buying an additional 65 shares during the last quarter. Gryphon Financial Partners LLC purchased a new position in shares of Stryker during the fourth quarter worth about $348,000. TrinityPoint Wealth LLC increased its position in shares of Stryker by 2.5% during the fourth quarter. TrinityPoint Wealth LLC now owns 2,841 shares of the medical technology company’s stock worth $851,000 after purchasing an additional 70 shares in the last quarter. Assetmark Inc. lifted its holdings in shares of Stryker by 57.1% in the 4th quarter. Assetmark Inc. now owns 891 shares of the medical technology company’s stock valued at $267,000 after purchasing an additional 324 shares during the last quarter. Finally, SageView Advisory Group LLC boosted its position in shares of Stryker by 17.1% in the 4th quarter. SageView Advisory Group LLC now owns 1,627 shares of the medical technology company’s stock valued at $515,000 after purchasing an additional 237 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Glenn S. Boehnlein sold 20,000 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $333.00, for a total value of $6,660,000.00. Following the completion of the transaction, the chief financial officer now owns 2,852 shares in the company, valued at $949,716. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Stryker news, Director Ronda E. Stryker sold 190,000 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $323.46, for a total transaction of $61,457,400.00. Following the completion of the transaction, the director now owns 3,316,608 shares of the company’s stock, valued at $1,072,790,023.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Glenn S. Boehnlein sold 20,000 shares of the company’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total value of $6,660,000.00. Following the completion of the sale, the chief financial officer now owns 2,852 shares in the company, valued at $949,716. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 220,068 shares of company stock valued at $71,811,372. 5.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on SYK. The Goldman Sachs Group assumed coverage on Stryker in a research note on Thursday, May 30th. They issued a “neutral” rating and a $372.00 price objective for the company. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research report on Monday, September 16th. Barclays raised their price objective on shares of Stryker from $374.00 to $402.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Stifel Nicolaus reduced their target price on shares of Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Finally, Needham & Company LLC raised their price target on Stryker from $392.00 to $393.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $378.58.

Stryker Trading Down 0.1 %

NYSE:SYK opened at $364.81 on Friday. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $374.63. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.95 and a current ratio of 1.68. The stock has a fifty day moving average price of $345.12 and a two-hundred day moving average price of $342.89. The stock has a market capitalization of $138.97 billion, a price-to-earnings ratio of 41.64, a PEG ratio of 2.87 and a beta of 0.91.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. The business had revenue of $5.42 billion during the quarter, compared to the consensus estimate of $5.40 billion. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The business’s revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.54 EPS. As a group, sell-side analysts anticipate that Stryker Co. will post 12 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be issued a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date of this dividend is Monday, September 30th. Stryker’s dividend payout ratio is currently 36.53%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.